



NCC Pediatrics Continuity Clinic Curriculum: Immunizations

Goal:

To understand the pediatric immunization schedule—a component of the AAP Periodicity Schedule— and become familiar with special immunization cases.

Pre-Meeting Preparation:

- Review the following enclosures:
 - “Rationale for the Immunization Schedule: Why Is It the Way It Is?” (*Pediatrics in Review*, 2019)
 - Recommended Child and Adolescent Immunization Schedule, 2024 (CDC)
- Prepare an example of a “**Vaccine Myth or Misconception**” and your thoughts about how to respond to a parent who has these concerns. *You may use the Extra-credit links or your own experiences as a guide.*

Conference Agenda:

- Complete “Immunization Cases”
- **Round-table discussion** of “Vaccine Myths & Misconceptions”—*each resident should list their example; the group should help offer ways to counsel parents.*
- **Optional:** Review how to transcribe immunizations in MHS Genesis.

Extra-Credit:

- [CDC- Vaccine Safety Concerns](#); [CDC- Parents FAQ's](#)
- "Vaccine Safety: Medical Contraindications, Myths, and Risk Communication" (*PIR*, 2015)
- [AAP & Immunizations](#) (*vaccine-preventable diseases, vaccines & safety, etc.*)
- [CDC Vaccine Abbreviations \(U.S\)](#) (*good for decoding shot records*) and [International Decoding](#)
- "Rationale for the Immunization Schedule: Why Is It the Way It Is"? (*PIR*, 2019)
- [Immunization Coverage](#) (*World Health Organization*)
- "Impact of Routine Childhood Immunization in Reducing Vaccine Preventable Diseases in the United States" (*Pediatrics*, 2022)
- "Strategies for Improving Vaccine Communication and Uptake" (*AAP Clinical Report*, 2024)
- "Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization" (*Lancet*, 2024)

Parent Handouts:

[Vaccine Safety](#)

[Answers to Common Questions](#)

[Vaccine Refusal Document \(AAP\)](#)

Rationale for the Immunization Schedule: Why Is It the Way It Is?

Varun U. Shetty, MD,* Parul Chaudhuri, MD,[†] Camille Sabella, MD[‡]

*Department of Internal Medicine–Pediatrics [†]Department of Internal Medicine, Case Western Reserve University–MetroHealth Medical Center, Cleveland, OH

[‡]Center for Pediatric Infectious Diseases, Cleveland Clinic Children's Hospital, Cleveland, OH

Education Gaps

1. Clinicians must understand the rationale for the current immunization schedule.
2. Clinicians must understand the basic immunologic responses associated with the various vaccine components.

Objectives After completing this article, readers should be able to:

1. Understand the basic concepts of vaccination immunology.
2. Provide the rationale for age at first vaccine dose.
3. Provide the rationale for spacing out vaccines at 4 to 8 weeks.
4. Explain the rationale for primary series and booster combination.
5. Explain why vaccinations do not need to be started over again during catch-up.

INTRODUCTION

Vaccines use the knowledge of the immune system to mimic infection, generate immunologic memory, and prepare the body for future infections. An ideal vaccine provides lifelong immunity from disease and protects against multiple strains of the same disease; it is safe, inexpensive, stable, and preferably not administered via injection. (1)

The main objective of the vaccination schedule is to protect individuals from disease by providing immunity before they acquire disease. (2) Long-term immunity is important in determining the effectiveness of the immunization schedule. Along with this, short-term protection, local prevalence and incidence, disease epidemiology, safety, and programmatic aspects (including number of doses, funding, organization, and cost) are important factors in determining the immunization schedule. (3)(4)

Development of vaccine schedules is based on a large body of basic sciences and epidemiologic research. There is constant review of evidence, adverse events, and epidemiology by a panel of experts.

AUTHOR DISCLOSURE Drs Shetty, Chaudhuri, and Sabella have disclosed no financial relationships relevant to this article. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.

ABBREVIATIONS

APC	antigen-presenting cell
BCG	bacille Calmette–Guérin
CDC	Centers for Disease Control and Prevention
DC	dendritic cell
DTaP	diphtheria–tetanus–acellular pertussis
Hep B	hepatitis B
Hib	<i>Haemophilus influenzae</i> type b
IPV	inactivated polio vaccine
MMR	measles–mumps–rubella
OPV	oral polio vaccine
PCV13	13-valent pneumococcal conjugate vaccine
PS	polysaccharide
Tfh	follicular T helper cell
VAPP	vaccine-associated paralytic poliomyelitis
WHO	World Health Organization

To understand how vaccines provide protection, it is important to understand the essential components that compose the immune system and how the immune system generates a response to perceived pathogens.

OVERVIEW OF THE IMMUNE SYSTEM

The immune system can be classified into innate and adaptive immune systems (Fig 1). The innate immune system is a more primitive form of defense that includes physical, physiological, and cellular barriers. Although the innate immune system is the body's first line of defense and can act quickly, it is nonspecific. In contrast, the adaptive immune system is a sophisticated, highly specific form of defense that is capable of recognizing billions of antigens. (5)

The cellular component of innate immunity predominantly involves cells such as natural killer cells and immature dendritic cells (DCs) that attack and phagocytose foreign antigens and damaged cells of the body. (5) However, recognition of foreign/pathogenic antigens by these cells is limited to common pathogen structures that are readily recognized as non-self or dangerous. (3)(5)(6)(7) This innate response is followed by an adaptive response, with antigen-presenting cells (APCs) forming a critical link between the 2 systems. (7) The APCs specialize in processing and presenting antigens to T cells. The DCs are important examples of APCs. Components that activate APCs and the remainder of the innate immune system are similar. (7)

An immature DC undergoes activation when it encounters an antigen identified as foreign. Activated DCs experience a change in their surface homing receptors, resulting in migration to lymph nodes, where they encounter T and B cells and begin an immune reaction cascade. At this point,

the adaptive immune system takes over from the innate immune system. Sometimes, the adaptive immune system can directly act on an antigen without needing an APC to present the antigen. A common example of this is the production of antibodies to polysaccharide (PS) vaccine antigens by B lymphocytes.

The adaptive system response takes more time to develop but lasts longer and produces a more robust immune response to foreign antigens. The adaptive immune system involves a targeted response to foreign antigens via T and B cells, and it interacts with the innate immune system. (3)(8) Immunologic memory (mainly B-cell memory, discussed later herein) allows rapid recognition and production of antibodies to pathogenic antigens when encountered in the future, and prevents disease. (3) This response is the major target of vaccinations. The basic tenet of vaccines is to induce effective, long-lasting immunity by triggering the adaptive immune response.

PROCESS OF GENERATION OF IMMUNITY TO VACCINE ANTIGENS

There are 2 types of responses to vaccine antigens: T-cell-dependent responses and T-cell-independent responses. The vaccine antigen is critical in determining whether the response is T-cell-dependent or T-cell-independent and, therefore, its immunogenicity (Fig 2). If the vaccine antigen is a protein antigen, such as a live attenuated virus or a protein such as hepatitis A vaccine, it will activate both B cells (that produce antibodies) and T cells. This is called a T-cell-dependent response. Polysaccharide vaccines such as 23-valent pneumococcal vaccine antigens directly trigger B cells, resulting in the production of antibodies by B cells




Figure 1. The immune system can be broadly classified into innate and adaptive, and both systems work with much interaction with each other.

without generation of immune memory. This is called a T-cell-independent response because it does not require T cells to mediate its action. Understanding the process of generation of immunity to vaccine antigens is important in understanding the vaccination schedule (Fig 3). T-cell involvement or T-cell-dependent reactions are indispensable for effective immune memory. Immune memory allows the immune system to act rapidly and specifically when the same infection is encountered in the future.


T-CELL-DEPENDENT REACTION

Live vaccines, killed vaccines, proteins, and PS conjugates generate a T-cell-dependent response. The DCs interact

with the vaccine antigen when it is first delivered. The DCs are found abundantly in muscle tissue, which is why the intramuscular route is preferred during vaccination. (3) Once in contact with a foreign antigen, DCs exhibit several different receptors on their cell surfaces. These activated DCs travel to the lymph node germinal centers and activate follicular T helper cells (Tfh cells) and B cells. The B cells in the lymph nodes are not naive but have already encountered the antigen while circulating through blood. After their encounter with the antigen, they become antigen-specific and migrate to lymph nodes, where they are then ready to receive further stimuli from Tfh cells.

The Tfh cells induce massive proliferation of B cells. An initial reaction results in the production of antibodies by B

T-cell-independent



T-cell-dependent




Figure 2. Vaccine antigens trigger either a T-cell-dependent response or a T-cell-independent response. T-cell-dependent responses result in immune memory, the reason why most vaccines today are live, protein, or conjugate vaccines that generate T-cell-dependent responses. Only polysaccharide antigens generate T-cell-independent responses.




Figure 3. Overview of T-cell–dependent and T-cell–independent responses to vaccine antigen: T-cell–dependent response is triggered by protein antigens (live viruses, surface proteins, etc). The antigen activates dendritic cells and B cells, both of which travel to lymph node germinal centers. Here, activated dendritic cells stimulate follicular T helper cells, which then induce massive proliferation of B cells, which then become either memory B cells or plasma cells that produce antibodies.

cells 2 weeks after the first antigen exposure. (3)(9) A significant portion of these B cells become either plasma cells that produce antigen-specific immunoglobulin G antibodies or memory B cells that will lie dormant until faced with the exact antigen for which they were made. (3)(5)

Antigen exposure and subsequent interactions of B cells, Tfh cells, and DCs in the lymph nodes form the germinal center reaction, which is a critical part of the primary response. It takes approximately 3 to 6 weeks before the primary response self-terminates through feedback mechanisms. Doses in the priming series of vaccines are

separated by a minimum of 4 weeks (usually 8 weeks or 2 months) so that they do not interfere with primary response waves in germinal centers.

After the germinal center reaction, B cells get signals from T cells and become either memory B cells or plasma cells that produce antigen-specific antibodies. The plasma cells then migrate to the bone marrow. Memory B cells take months to develop antigen specificity. For example, memory B cells generated from the measles vaccine will be active only against measles. These memory B cells do not produce antibodies. Instead, they find homes in the spleen and lymph nodes and wait until presented with an antigen, and then rapidly differentiate to plasma cells and produce antibodies specifically targeting that antigen. Over a person's lifetime there may be several billion memory B-cell types created that target specific antigens. (5) The efficient specificity that memory B cells possess results from a process called *affinity maturation* that takes approximately 4 to 6 months to develop. (3)

Memory B-cell production is important, as quantitative levels of antibodies to protein antigens wane over time. The exception to this is antibodies against live viruses; protective titers can be found decades after vaccination. (3) This may be because of the self-propagation of live viruses that results in continued stimulation of the immune system and explains the lifelong immunity to live virus vaccines such as measles vaccine after immunization.

The success of a vaccine depends on its ability to elicit a specific, robust, and long-lasting T-cell-dependent response. Most vaccines in use today are live attenuated viruses such as measles-mumps-rubella (MMR), varicella, rotavirus, and oral polio vaccine (OPV); protein antigens such as diphtheria-tetanus-acellular pertussis (DTaP) and hepatitis B (Hep B); or PS conjugates such as 13-valent pneumococcal conjugate vaccine (PCV13) and *Haemophilus influenzae* type b (Hib).

T-CELL-INDEPENDENT REACTION

Vaccines that use PS antigens elicit T-cell-independent immune responses. Most PS vaccines in use today use a carbohydrate "piece" from the bacterial cell wall. After injection into muscle, the PS antigen finds its way to B cells in the spleen and lymph nodes and triggers differentiation of B cells into plasma cells, which eventually leads to the production of poor-affinity antibodies. This takes approximately 1 week, results in the production of antibodies, is independent of signals from Th cells, and is quick to produce antibodies without generation of immune memory.

Several pure PS vaccines were used in the past. However, because of the poor immune response they generate, most PS vaccines are now conjugated with a protein or a substance that enhances immunogenicity (adjuvant). (3) When a PS is conjugated with a protein or adjuvant, it acts like a protein antigen and generates a T-cell-dependent response. Immunogenicity of pure PS vaccines before age 2 years is poor. (10) The PCV13, a PS conjugate vaccine, is recommended at 2, 4, and 6 months because it generates good immunity before age 2 years. However, the 23-valent pneumococcal PS, a pure PS vaccine against pneumococcus, is given only after 2 years of age. A pure PS vaccine is suitable when rapid induction of immunity is required; for example, a traveler wanting temporary but rapid immunity from *Salmonella typhi* when visiting an endemic region.

RATIONALE FOR THE IMMUNIZATION SCHEDULE

The underlying goal of the immunization schedule is to achieve effective, lasting immunity against diseases. This means inducing lasting immunologic memory and production of persistent antibodies. Although a prerequisite for understanding the rationale for the immunization schedule, learning the immune response to a vaccine antigen is not sufficient by itself. One needs to know local epidemiologic patterns of disease to optimize the timing of priming and booster doses. Programmatic considerations, such as grouping of vaccines, cold chain storage, number of doses, and interference by competing antigens in generating immune responses, all play roles in developing a vaccination schedule.

We will consider dosing regimens of some important vaccines used in the regimen and explain why they are dosed in their current form.

Age at First Dose and the 2-, 4-, 6-month Schedule

Priming doses are required to generate immune memory. These are the initial doses that generate a germinal center reaction and result in production of memory B cells and plasma cells that produce antibodies.

In the United States, priming doses of DTaP, Hib, rotavirus, PCV13, and inactivated polio vaccine (IPV) are all given at 2, 4, and 6 months, although some formulations of Hib and rotavirus are given at 2 and 4 months. Infants younger than 1 year have the greatest risk of mortality from pertussis, and mortality from diphtheria is highest in those younger than 10 years. (11)(12) Similarly, the prevalence of bacterial meningitis before the widespread use of Hib and pneumococcal conjugate vaccines was the highest in the

first year of life. Therefore, protection against these infections throughout the first year of life is essential.

Immunization before 6 weeks of age for most antigens results in a weaker response and poorer immune persistence, mainly because of the immaturity of the immune system. (3)(13) The magnitude of an antibody response, ie, antibody titers, is higher with increasing age at first dose. (13) However, the 6-, 10-, 14-week schedule along with the addition of a booster dose generates equivalent immune memory compared with schedules that start at or after 2 months of age and is more appropriate depending on local epidemiology of disease. (14)(15)(16) Thus, the recommended age to give most vaccines is at 2 months in the United States, at 3 months in some European countries, and at 6 weeks where the burden of disease is high. (13)(17)(18) Hepatitis B, bacille Calmette-Guérin (BCG), and OPV are exceptions to this; they are all given at birth and are discussed in more detail later in this article.

A minimum of 3 weeks between primary doses prevents interference of primary waves of immune response. (3) This is because a primary response self-terminates in 3 to 6 weeks. Vaccines are spaced out at 4- to 8-week intervals to avoid competing immune responses between primary waves of germinal center reaction. Several studies have examined different priming schedules (eg, a 3- and 5-month 2-dose schedule, as well as 2-, 4-, 6-month and 2-, 3-, 4-month schedules), and these studies suggest that all schedules generate immune memory. (13)

The longer the interval between doses, and the older the infant, the longer the persistence of response to the vaccine. (3) Closely spaced vaccine doses (1–2 weeks) would give protection sooner, which is useful when rapid induction of immunity is required. (3) But this immune response would not be as long-lasting as when the doses are spaced out at 4 to 8 weeks. Vaccine schedules try to achieve a balance between early protection and best immune response by spacing out vaccines enough to allow immune maturity but early enough to protect before acquisition of disease.

The World Health Organization (WHO) Expanded Program on Immunization schedule recommends beginning diphtheria-tetanus-pertussis whole cell or DTaP vaccine as early as 6 weeks, and providing 3 priming doses at least 4 weeks apart, with the first booster dose between 12 and 23 months. (17) This is used by many developing countries where the incidence and prevalence of diphtheria and pertussis are higher than in industrialized nations. Starting at 6 weeks provides very early immunity, but the immune system is not as mature as it would be if started at 2 months. However, studies have shown that the 6-, 10-, 14-week schedule provides good immune response and that the

addition of a booster dose generates equivalent immune memory compared with schedules that start at or after 2 months of age and is more appropriate for local epidemiology of disease. (13)(19)

Regimens in different countries are based on principles of vaccination immunology and differ according to local epidemiology and programmatic preferences (Table 1).

Table 2 lists priming dose regimens for diphtheria-tetanus-pertussis vaccine in various countries. Although this list is not exhaustive, it demonstrates the use of knowledge of vaccination immunology and local epidemiology to develop a vaccine regimen. Note that the doses are separated by a minimum of 4 weeks in all recommended schedules to prevent interference in primary waves of immune response.

Prime-Boost Schedule

As reviewed previously herein, affinity maturation is the process by which memory B cells complete the process of developing antigen specificity. This process takes approximately 4 to 6 months. Antibodies generated in the initial wave of primary response during priming doses eventually wane over a period of months.

Allowing at least a 6-month gap between the last primary dose and the first booster dose allows completion of the affinity maturation process and development of highly specific memory B cells. The longer the gap between the primary and booster doses, the better the immune persistence. (3)

TABLE 1. Factors Influencing the Vaccination Schedule (4)

Vaccination immunology:

- Immune maturity, maternal antibodies, magnitude of immune response, and immune memory are important considerations in determining vaccination schedules

Local epidemiology:

- Ideally, the dose of vaccine should precede the earliest, most susceptible age at acquisition of disease
- High incidence and prevalence generally favors earlier immunization
- Eradication of disease/infection could lead to elimination of use of certain vaccines, eg, small pox vaccine

Programmatic considerations:

- Organization of vaccination drives, educating local practitioners
- Availability of combined vaccines
- Cost (eg, acellular pertussis is more expensive than whole cell pertussis), maintaining cold storage, and heat stability are some important factors influencing the inclusion and timing of vaccines in the schedule

TABLE 2. Comparison of Diphtheria-Tetanus-Pertussis Priming Dose Regimens

COUNTRY	PRIMING DOSE REGIMEN
United States	2 mo (8 wk), 4 mos (16 wk), 6 mo (24 wk)
United Kingdom	2 mo (8 weeks), 3 mo (12 wk), 4 months (16 wk) (13)
Italy	3 mo (12 wk), 5–6 mo (20–24 wk) (13)
World Health Organization Expanded Program on Immunization	Begin at 6 wk, 4-wk minimum interval between doses, 3 priming doses in total

A booster dose stimulates immune memory and triggers memory B cells to become plasma cells and generate antibodies. These antibodies persist in the blood for several months, even years, and neutralize antigens produced by pathogenic microbial agents before they have an opportunity to cause disease.

Spreading out vaccine doses for better immune memory needs to be balanced with providing effective protection before an exposed child develops disease. Therefore, local epidemiology must be taken into consideration when determining vaccine timing.

All schedules recommend booster dose administration at least 6 months after the last priming dose. (2)(17) Most schedules space out booster doses further from priming doses because longer intervals between doses result in longer immune memory. For example, in the United States, the DTaP booster is given 9 months after the last priming dose and the Hib booster is given at least 6 months after the last priming dose. (18) The WHO Expanded Program on Immunization schedule also recommends pertussis booster at 1 to 6 years of age, although it states that the booster dose must be separated by at least 6 months. (17) The Centers for Disease Control and Prevention (CDC) also recommends spacing out the booster dose by at least 6 months in the case of delayed immunizations. (18) This is to allow for earlier protection without compromising on immune memory.

In summary, booster doses allow for maintenance of sustained antibody levels and should be given at least 6 months after the last priming dose to allow for affinity maturation.

MMR and Varicella Vaccines

The MMR and varicella vaccines are examples of how giving a live virus vaccine generates longer immunologic memory. Although live virus, killed virus (eg, IPV), protein (eg,

tetanus toxoid), and PS conjugate (eg, Hib, PCV13) vaccines all elicit T-cell–dependent responses, generate immunologic memory, and offer effective, long-lasting protection, live vaccines always generate the most powerful immune responses. This is because the amount of antigen exposure results in multiple primary responses all over the body, as well as persistent exposure to the pathogen that generates more powerful antibody responses. Live virus vaccine is also the only type of vaccine that generates a CD8 response, which results in direct killing of infected cells and indirect destruction of cells via cytokines. (3) Live vaccines generate lifelong immunity not only because they generate the T-cell–dependent response that generates immune memory but also because the virus multiplies and persists in the body, thus constantly exposing the host to the antigen and stimulating the immune system. This results in survival of plasma cells in bone marrow for long periods, which generate antibodies for decades. Only live vaccines generate an antibody response that is detectable for decades, even in the absence of subsequent antigen exposure.

The MMR and varicella vaccines are given only after 6 months of age (preferably after 12 months). This is to avoid neutralization by maternal antibodies and a poor immune response from an immature immune system. Presence of maternal antibodies plays an important role in the ability of the MMR vaccine to generate immunogenicity. These antibodies usually disappear between 6 and 9 months of age. They interfere in replication of the live attenuated measles virus, thereby preventing the development of multiple foci of primary reaction. Maternal antibodies to measles significantly reduce immune response and can affect vaccine efficacy. In addition, studies have demonstrated that infants younger than 6 months of age do not mount a good immune response to the MMR vaccine, even in the absence of maternal antibodies. (20)

Multiple studies have shown the effect of maternal antibodies on the efficacy of the MMR vaccine: 98% of children developed protective antibodies to measles if vaccinated after 12 months of age. (20) and almost all children developed protective antibodies to measles with a first vaccine dose at 6 months and a second dose at 12 months or a first dose at 15 to 17 months and a second at 4 to 6 years. (20) A second dose is given to protect the minority of children (~5%) who do not develop protective antibodies with the first dose. A booster dose, therefore, is not required for MMR vaccine in childhood.

The CDC and the American Academy of Pediatrics, therefore, recommend administration of MMR and varicella vaccines at 12 months of age, with a second dose at 4 to 6 years. However, if the child is traveling to a

measles-endemic area, MMR vaccine can be given as early as 6 months of age. In such cases, revaccinating at 12 to 15 months and giving a third dose at least 4 weeks later are required.

Vaccines at Birth

In the United States, only the Hep B vaccine is given at birth. Studies have shown that in children with birthweight of more than 2,000 g, a dose of Hep B at birth with subsequent doses at 1 to 2 months and 6 to 12 months demonstrated an excellent immune response. (21) Before the routine use of Hep B vaccines, 30% to 40% of children with chronic Hep B acquired the disease via perinatal or early childhood transmission. (22) Moreover, almost half of all new mothers who are positive for Hep B surface antigen are not identified. (22) This underscores the need to protect infants and children when they are most vulnerable. Although preterm infants weighing less than 2,000 g do not have good immune responses with a birth dose of Hep B vaccine, all premature infants, irrespective of gestational age or birthweight, are protected with the 3-dose Hep B vaccine series started at 1 month of chronological age. (21) Therefore, the CDC recommends that all infants weighing more than 2,000 g must get the first dose of Hep B within 24 hours of birth and preterm infants weighing less than 2,000 g at birth must get the first dose at 1 month of age. (23)

Vaccines given at birth in other countries include OPV and BCG. The OPV has been shown to generate good gut immunity when given at birth even in the presence of maternal antibodies. (24) It is safe and provides the earliest protection to infants from polio. (24)(25) It is indispensable in areas where poliomyelitis is endemic, such as Nigeria, Afghanistan, and Pakistan, or where there is risk of importation of disease from neighboring countries. (26) However, OPV is associated with rare adverse effects of vaccine-associated paralytic poliomyelitis (VAPP) and vaccine-derived polioviruses. The incidence of VAPP was higher in industrialized countries with the first dose of OPV, most likely due to higher immunogenicity of vaccine antigen compared with low- to middle-income countries. The reason for this is not understood well, but a higher prevalence of maternal antibodies in low-income settings, and competing infections might be contributing factors. (27)(28) Therefore, although OPV has been very effective in eradication of polio, it is not necessary in countries that have already achieved poliomyelitis eradication, have low risk of polio importation and transmission, and continue to have good rates of immunization. The IPV does not cause VAPP. It is recommended that an IPV-only schedule may be considered in such countries, including the United States. (27)

The CDC does not recommend routine BCG vaccine to children born in the United States because the general risk of transmission of tuberculosis is low. (29) The WHO does acknowledge the limited efficacy of BCG in that it does not protect from primary infection or reactivation of latent tuberculosis, a major source of tuberculosis infection in the community. (30) However, BCG vaccine does protect children from miliary tuberculosis and tuberculous meningitis in the first 5 years of life. (25) The BCG vaccine also is safe, which is why it continues to be recommended at birth in regions where risk of tuberculosis transmission remains high. (25) The OPV and BCG vaccines are good examples of how local epidemiology of disease influences timing as well as type of vaccines included in vaccination schedules.

Catch-up Vaccines

It is not recommended that the immunization schedule be started again in patients with delayed immunization. This is due to the generation of immune memory. Although antibody titers wane with time, memory B cells in the spleen and lymph nodes readily recognize the antigen with subsequent exposures to vaccine antigens and produce antibodies. A long time between priming doses induces better immunologic memory. However, because of the long time between doses, children with delayed vaccines are susceptible to serious vaccine-preventable infections. Therefore, the CDC catch-up schedule recommends a minimum of 4 weeks between catch-up doses of vaccines and that the vaccination schedule does not have to be started all over again. (18)

The same CDC catch-up schedule can be applied to children who have no immunizations until a later stage. Because the primary reaction in lymph nodes lasts 3 to 6 weeks, an accelerated schedule with priming doses separated by a minimum of 4 weeks can be used. However, age at the start of vaccines, epidemiology, and national immunization schedule recommendations should be considered when deciding on the optimal vaccine schedule for such children.

VACCINE EXEMPTIONS AND DELAYS

There is strong evidence that skipping vaccine doses increases the risk of acquiring vaccine-preventable diseases such as measles and pertussis. (31)(32) According to the American Academy of Pediatrics, "There is no 'alternative' immunization schedule. Delaying vaccines only leaves a child at risk of disease for a longer period of time; it does not make vaccinating safer." (33) It is best to adhere to

recommended schedules and discourage alternate, unvalidated schedules.

CONCLUSION

Development of vaccine schedules is based on a large body of basic sciences and epidemiologic research. There is constant review of evidence, adverse events, and epidemiology by panels of experts. The immunization schedule is updated accordingly. It is critical that we understand the basis of the vaccination schedule so that we can better educate ourselves and our patients, and use available evidence to best protect them.

Summary

- Based on consensus, the main objective of vaccines is to provide protection against vaccine-preventable diseases by providing effective short- and long-term immunity from disease. (4)
- Based on strong evidence, there are 2 types of responses to vaccine antigens: T-cell-dependent and T-cell-independent responses. The T-cell-dependent response is critical in generating effective immunologic memory. (3)
- Based on strong evidence, T-cell-independent response is triggered by polysaccharide (PS) vaccine antigens. PS antigens trigger B cells to differentiate into plasma cells that produce antigen-specific antibodies that are short-lived. There is no generation of immune memory in this type of response.
- Most vaccines are developed with the goal of triggering a T-cell-dependent response.
- Based on strong evidence, vaccine antigen type is crucial in determining whether the generated response will be T-cell-dependent or T-cell-independent. Live virus, protein, and polysaccharide conjugate vaccines all generate T-cell-dependent responses. (3)(5)

- Based on strong evidence, immune response and memory are both better with administering vaccines after 2 months of age. (13)
- Based on strong evidence, vaccines can be started at 6 weeks of age if the risk of contracting disease is high, provided all 3 priming doses and booster doses are appropriately given thereafter. (13)(17)
- Based on strong evidence, immune memory generation allows us to continue vaccine schedules rather than start over in children with delayed vaccinations. (3)
- Based on strong evidence, vaccine exemption increases the risk of acquiring vaccine-preventable diseases. (31)(32)
- The immunization schedule is based on the guiding principles of vaccination immunology, local disease epidemiology, and programmatic needs, which ultimately result in an effective and pragmatic vaccination schedule.

To view teaching slides that accompany this article, visit <http://pedsinreview.aappublications.org/content/40/1/26.supplemental>.

Rationale for the Immunization Schedule: Why Is It the Way It Is?

Varun U. Shetty, MD,* Parul Chaudhury, MD,† Camille Sabella, MD‡

*Internal Medicine Pediatrics, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

†Internal Medicine, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

‡Center for Pediatric Infectious Diseases, Cleveland Clinic Children's Hospital, Cleveland, OH

Pediatrics in Review

American Academy of Pediatrics
DEDICATED TO THE HEALTH OF ALL CHILDREN

References for this article are at <http://pedsinreview.aappublications.org/content/40/1/26>.

PIR Quiz

There are two ways to access the journal CME quizzes:

1. Individual CME quizzes are available via the blue CME link under the article title in the Table of Contents of any issue.
2. To access all CME articles, click "Journal CME" from Gateway's orange main menu or go directly to: <http://www.aappublications.org/content/journal-cme>.
3. To learn how to claim MOC points, go to: <http://www.aappublications.org/content/moc-credit>.

1. While reviewing your daily schedule you note that a patient is scheduled to return for vaccines just 2 weeks after the previous dose. You ask your nurse to reschedule the patient and explain that the minimum interval between doses of all vaccines is at least 4 weeks. Which of the following best describes the reason a minimum of 4 weeks is required between vaccine doses?
 - A. Antigen-presenting cells of the innate immune system require approximately 4 weeks to attack vaccine antigens.
 - B. Antigen-presenting cells of the innate immune system require approximately 4 weeks to travel to muscle.
 - C. Interference between successive waves of priming responses in the lymph nodes is avoided by minimum spacing of 4 weeks.
 - D. Memory B cells need approximately 4 weeks to develop antigen specificity.
 - E. Memory B cells need approximately 4 weeks to migrate to the spleen and lymph nodes.
2. A patient is seen in the clinic for a 6-month health supervision visit. After receiving the required immunizations, the clinician provided the mother with anticipatory guidance and instructed her that the baby will be due for a health supervision visit at 9 months of age, at which time he does not need any vaccines. Booster vaccines will be provided at the 12- and 15-month health supervision visits. The nurse informs the clinician that at checkout the mother is inquiring whether the diphtheria-tetanus-acellular pertussis (DTaP) #4 can be given at the 9-month health supervision visit to space out the vaccines. The clinician explains to the nurse that the interval between DTaP #3 and DTaP #4 must be at least 6 months. Which of the following is the most appropriate explanation for the rationale of this recommendation?
 - A. A shorter interval between the primary series and booster dose will result in a severe local reaction at the injection site.
 - B. A shorter interval between the primary series and booster dose will result in a strong immune reaction.
 - C. A shorter interval between the primary series and booster dose will increase immune persistence.
 - D. A 6-month interval before the booster dose allows the development of highly specific memory B cells for longer immune memory.
 - E. A 6-month interval before the booster dose is necessary to generate the T-cell-independent antibody response.
3. The mother of a 6-month-old boy brings him to the clinic because the family will be traveling internationally next month and will be abroad for 8 weeks. Which of the following is the best plan for immunizing this patient?
 - A. Give measles immune globulin now.
 - B. Give measles immune globulin 1 week before travel.
 - C. Give measles-mumps-rubella (MMR) #1 now and MMR #2 at 4 to 6 years of age.
 - D. Give MMR #1 now and MMR #2 at 12 to 15 months of age.
 - E. Give MMR #1 now, MMR #2 at 12 to 15 months, and MMR #3 at least 4 weeks later.

REQUIREMENTS: Learners can take *Pediatrics in Review* quizzes and claim credit online only at: <http://pedsinreview.org>.

To successfully complete 2019 *Pediatrics in Review* articles for AMA PRA Category 1 CreditTM, learners must demonstrate a minimum performance level of 60% or higher on this assessment. If you score less than 60% on the assessment, you will be given additional opportunities to answer questions until an overall 60% or greater score is achieved.

This journal-based CME activity is available through Dec. 31, 2021, however, credit will be recorded in the year in which the learner completes the quiz.



2019 *Pediatrics in Review* now is approved for a total of 30 Maintenance of Certification (MOC) Part 2 credits by the American Board of Pediatrics through the AAP MOC Portfolio Program. Complete the first 10 issues or a total of 30 quizzes of journal CME credits, achieve a 60% passing score on each, and start claiming MOC credits as early as October 2019. To learn how to claim MOC points, go to: <http://www.aappublications.org/content/moc-credit>.

4. While reviewing the records of a new patient from Africa, you note that he received his first dose of oral polio vaccine (OPV) at birth. Which of the following best explains the approach to immunization of newborns?
- A. Newborns in other countries may appropriately receive OPV and/or bacille Calmette-Guérin (BCG) vaccines based on the local epidemiology of disease.
 - B. Newborns should not receive any vaccines other than hepatitis B due to the immaturity of their immune system.
 - C. Newborns should not receive any vaccines other than hepatitis B due to interference by maternal antibodies.
 - D. Newborns should not receive BCG due to risk of dangerous adverse effects.
 - E. Newborns should routinely receive hepatitis B vaccine at birth only if the mother is known to be hepatitis B surface antigen positive.
5. A 4-year-old boy has returned to your practice after living in Haiti for several years. His mother reports that he had no medical care during that time. Your records indicate that he received his 2- and 4-month vaccines only before leaving the United States. Which of the following describes the most appropriate approach to further immunization of this child?
- A. Further immunization should be deferred until the next visit to determine whether the parent can obtain documentation of additional vaccines.
 - B. Some immunizations should be deferred to avoid overwhelming the immune system with too many antigens.
 - C. The vaccine schedule should be restarted because the interruption in the schedule is too long.
 - D. The vaccine schedule should be restarted because the priming series is incomplete.
 - E. The vaccine schedule should be resumed today, giving all age-appropriate and catch-up vaccines without repeating any previous doses.

Rationale for the Immunization Schedule: Why Is It the Way It Is?

Varun U. Shetty, Parul Chaudhuri and Camille Sabella

Pediatrics in Review 2019;40;26

DOI: 10.1542/pir.2018-0033

Updated Information & Services	including high resolution figures, can be found at: http://pedsinreview.aappublications.org/content/40/1/26
Supplementary Material	Supplementary material can be found at: http://pedsinreview.aappublications.org/content/suppl/2018/12/28/40.1.26.DC1
References	This article cites 15 articles, 2 of which you can access for free at: http://pedsinreview.aappublications.org/content/40/1/26.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Medical Education http://classic.pedsinreview.aappublications.org/cgi/collection/medical_education_sub Journal CME http://classic.pedsinreview.aappublications.org/cgi/collection/journal_cme Infectious Disease http://classic.pedsinreview.aappublications.org/cgi/collection/infectious_diseases_sub Vaccine/Immunization http://classic.pedsinreview.aappublications.org/cgi/collection/vaccine:immunization_sub Preventive Medicine http://classic.pedsinreview.aappublications.org/cgi/collection/preventative_medicine_sub
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: https://shop.aap.org/licensing-permissions/
Reprints	Information about ordering reprints can be found online: http://classic.pedsinreview.aappublications.org/content/reprints



Rationale for the Immunization Schedule: Why Is It the Way It Is?

Varun U. Shetty, Parul Chaudhuri and Camille Sabella

Pediatrics in Review 2019;40;26

DOI: 10.1542/pir.2018-0033

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pedsinreview.aappublications.org/content/40/1/26>

Pediatrics in Review is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1979. Pediatrics in Review is owned, published, and trademarked by the American Academy of Pediatrics, 345 Park Avenue, Itasca, Illinois, 60143. Copyright © 2019 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0191-9601.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

UNITED STATES
2024

Vaccines and Other Immunizing Agents in the Child and Adolescent Immunization Schedule*

Monoclonal antibody	Abbreviation(s)	Trade name(s)
Respiratory syncytial virus monoclonal antibody (Nirsevimab)	RSV-mAb	Beyfortus™
Vaccine	Abbreviation(s)	Trade name(s)
COVID-19	1vCOV-mRNA	Comirnaty®/Pfizer-BioNTech COVID-19 Vaccine
	1vCOV-aPS	Spikevax®/Moderna COVID-19 Vaccine Novavax COVID-19 Vaccine
Dengue vaccine	DEN4CYD	Dengvaxia®
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel® Infanrix®
<i>Haemophilus influenzae</i> type b vaccine	Hib (PRP-T)	ActHIB® Hiberix®
	Hib (PRP-OMP)	PedvaxHIB®
Hepatitis A vaccine	HepA	Havrix® Vaqta®
Hepatitis B vaccine	HepB	Engerix-B® Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)	IIV4	Multiple
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II® Priorix®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-CRM	Menveo®
	MenACWY-TT	MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C	Bexsero®
	MenB-FHbp	Trumenba®
Meningococcal serogroup A, B, C, W, Y vaccine	MenACWY-TT/ MenB-FHbp	Penbraya™
Mpox vaccine	Mpox	Jynneos®
Pneumococcal conjugate vaccine	PCV15	Vaxneuvance™
	PCV20	Prevnar 20®
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23®
Poliovirus vaccine (inactivated)	IPV	Ipol®
Respiratory syncytial virus vaccine	RSV	Abrysvo™
Rotavirus vaccine	RV1 RV5	Rotarix® RotaTeq®
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Tetanus and diphtheria vaccine	Td	Tenivac® Tdvax™
Varicella vaccine	VAR	Varivax®
Combination vaccines (use combination vaccines instead of separate injections when appropriate)		
DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix®
DTaP, inactivated poliovirus, and <i>Haemophilus influenzae</i> type b vaccine	DTaP-IPV/Hib	Pentacel®
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix® Quadracel®
	DTaP-IPV-Hib-HepB	Vaxelis®
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad®

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

How to use the child and adolescent immunization schedule

<h3>1</h3> <p>Determine recommended vaccine by age (Table 1)</p>	<h3>2</h3> <p>Determine recommended interval for catch-up vaccination (Table 2)</p>	<h3>3</h3> <p>Assess need for additional recommended vaccines by medical condition or other indication (Table 3)</p>	<h3>4</h3> <p>Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)</p>	<h3>5</h3> <p>Review contraindications and precautions for vaccine types (Appendix)</p>	<h3>6</h3> <p>Review new or updated ACIP guidance (Addendum)</p>
---	--	---	--	--	---

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), and National Association of Pediatric Nurse Practitioners (www.napnap.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html
- *General Best Practice Guidelines for Immunization* (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual

Scan QR code for access to online schedule



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

Table 1 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

Vaccine and other immunizing agents	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19–23 mos	2–3 yrs	4–6 yrs	7–10 yrs	11–12 yrs	13–15 yrs	16 yrs	17–18 yrs				
Respiratory syncytial virus (RSV-mAb [Nirsevimab])	1 dose depending on maternal RSV vaccination status, See Notes					1 dose (8 through 19 months), See Notes															
Hepatitis B (HepB)	1 st dose	← 2 nd dose →		← 3 rd dose →																	
Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)			1 st dose	2 nd dose	See Notes																
Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)			1 st dose	2 nd dose	3 rd dose	← 4 th dose →				5 th dose											
Haemophilus influenzae type b (Hib)			1 st dose	2 nd dose	See Notes	← 3 rd or 4 th dose, See Notes →															
Pneumococcal conjugate (PCV15, PCV20)			1 st dose	2 nd dose	3 rd dose	← 4 th dose →															
Inactivated poliovirus (IPV <18 yrs)			1 st dose	2 nd dose	← 3 rd dose →						4 th dose						See Notes				
COVID-19 (1vCOV-mRNA, 1vCOV-aPS)						1 or more doses of updated (2023–2024 Formula) vaccine (See Notes)															
Influenza (IIV4)						Annual vaccination 1 or 2 doses								Annual vaccination 1 dose only							
OR											Annual vaccination 1 or 2 doses		OR						Annual vaccination 1 dose only		
Influenza (LAIV4)																					
Measles, mumps, rubella (MMR)					See Notes		← 1 st dose →				2 nd dose										
Varicella (VAR)							← 1 st dose →				2 nd dose										
Hepatitis A (HepA)					See Notes		2-dose series, See Notes														
Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)													1 dose								
Human papillomavirus (HPV)													See Notes								
Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)				See Notes												1 st dose			2 nd dose		
Meningococcal B (MenB-4C, MenB-FHbp)											See Notes										
Respiratory syncytial virus vaccine (RSV [Abrysvo])											Seasonal administration during pregnancy, See Notes										
Dengue (DEN4CYD; 9-16 yrs)											Seropositive in endemic dengue areas (See Notes)										
Mpox																					

Range of recommended ages for all children
 Range of recommended ages for catch-up vaccination
 Range of recommended ages for certain high-risk groups
 Recommended vaccination can begin in this age group
 Recommended vaccination based on shared clinical decision-making
 No recommendation/not applicable

Table 2 Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2024

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. **Always use this table in conjunction with Table 1 and the Notes that follow.**

Children age 4 months through 6 years					
Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses			
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
Hepatitis B	Birth	4 weeks	8 weeks and at least 16 weeks after first dose minimum age for the final dose is 24 weeks		
Rotavirus	6 weeks Maximum age for first dose is 14 weeks, 6 days.	4 weeks	4 weeks maximum age for final dose is 8 months, 0 days		
Diphtheria, tetanus, and acellular pertussis	6 weeks	4 weeks	4 weeks	6 months	6 months A fifth dose is not necessary if the fourth dose was administered at age 4 years or older and at least 6 months after dose 3
<i>Haemophilus influenzae</i> type b	6 weeks	No further doses needed if first dose was administered at age 15 months or older. 4 weeks if first dose was administered before the 1 st birthday. 8 weeks (as final dose) if first dose was administered at age 12 through 14 months.	No further doses needed if previous dose was administered at age 15 months or older 4 weeks if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRP-T (ActHib®, Pentacel®, Hiberix®), Vaxelis® or unknown 8 weeks and age 12 through 59 months (as final dose) if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR if current age is 12 through 59 months and first dose was administered before the 1 st birthday and second dose was administered at younger than 15 months; OR if both doses were Pedvax-HIB® and were administered before the 1st birthday	8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1 st birthday.	
Pneumococcal conjugate	6 weeks	No further doses needed for healthy children if first dose was administered at age 24 months or older 4 weeks if first dose was administered before the 1 st birthday 8 weeks (as final dose for healthy children) if first dose was administered at the 1 st birthday or after	No further doses needed for healthy children if previous dose was administered at age 24 months or older 4 weeks if current age is younger than 12 months and previous dose was administered at <7 months old 8 weeks (as final dose for healthy children) if previous dose was administered between 7–11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was administered before age 12 months	8 weeks (as final dose) This dose is only necessary for children age 12 through 59 months regardless of risk, or age 60 through 71 months with any risk, who received 3 doses before age 12 months.	
Inactivated poliovirus	6 weeks	4 weeks	4 weeks if current age is <4 years 6 months (as final dose) if current age is 4 years or older	6 months (minimum age 4 years for final dose)	
Measles, mumps, rubella	12 months	4 weeks			
Varicella	12 months	3 months			
Hepatitis A	12 months	6 months			
Meningococcal ACWY	2 months MenACWY-CRM 2 years MenACWY-TT	8 weeks	See Notes	See Notes	
Children and adolescents age 7 through 18 years					
Meningococcal ACWY	Not applicable (N/A)	8 weeks			
Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis	7 years	4 weeks	4 weeks if first dose of DTaP/DT was administered before the 1 st birthday 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1 st birthday	6 months if first dose of DTaP/DT was administered before the 1 st birthday	
Human papillomavirus	9 years	Routine dosing intervals are recommended.			
Hepatitis A	N/A	6 months			
Hepatitis B	N/A	4 weeks	8 weeks and at least 16 weeks after first dose		
Inactivated poliovirus	N/A	4 weeks	6 months A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.	A fourth dose of IPV is indicated if all previous doses were administered at <4 years OR if the third dose was administered <6 months after the second dose.	
Measles, mumps, rubella	N/A	4 weeks			
Varicella	N/A	3 months if younger than age 13 years. 4 weeks if age 13 years or older			
Dengue	9 years	6 months	6 months		

Table 3 Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024

Always use this table in conjunction with Table 1 and the Notes that follow. Medical conditions are often not mutually exclusive. If multiple conditions are present, refer to guidance in all relevant columns. See Notes for medical conditions not listed.

Vaccine and other immunizing agents	Pregnancy	Immunocompromised (excluding HIV infection)	HIV infection CD4 percentage and count ^a		CSF leak or cochlear implant	Asplenia or persistent complement deficiencies	Heart disease or chronic lung disease	Kidney failure, End-stage renal disease or on Dialysis	Chronic liver disease	Diabetes	
			<15% or <200mm	≥15% and ≥200mm							
RSV-mAb (nirsevimab)		2nd RSV season	1 dose depending on maternal RSV vaccination status, See Notes				2nd RSV season for chronic lung disease (See Notes)	1 dose depending on maternal RSV vaccination status, See Notes			
Hepatitis B			Recommended for all age-eligible children who lack documentation of a complete vaccination series								
Rotavirus		SCID ^b	Not recommended for all children, but is recommended for some children based on increased risk for or severe outcomes from disease								
DTaP/Tdap	DTaP		Recommended for all age-eligible children, and additional doses may be necessary based on medical condition or other indications. See Notes.								
	Tdap: 1 dose each pregnancy		Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction								
Hib		HSCT: 3 doses	See Notes		See Notes		Contraindicated or not recommended *Vaccinate after pregnancy, if indicated				
Pneumococcal		Recommended for all age-eligible children, and additional doses may be necessary based on medical condition or other indications. See Notes.									
IPV		Recommended for all age-eligible children who lack documentation of a complete vaccination series									
COVID-19		See Notes									
IIV4		Recommended for all age-eligible children who lack documentation of a complete vaccination series									
LAIV4		Contraindicated or not recommended *Vaccinate after pregnancy, if indicated						Asthma, wheezing: 2–4 years ^c			
MMR	*	Contraindicated or not recommended *Vaccinate after pregnancy, if indicated									
VAR	*	Contraindicated or not recommended *Vaccinate after pregnancy, if indicated									
Hepatitis A		Recommended for all age-eligible children who lack documentation of a complete vaccination series									
HPV	*	3 dose series. See Notes									
MenACWY											
MenB											
RSV (Abrysvo)	Seasonal administration, See Notes	No Guidance/ Not Applicable									
Dengue											
Mpox	See Notes	Not recommended for all children, but is recommended for some children based on increased risk for or severe outcomes from disease									

 Recommended for all age-eligible children who lack documentation of a complete vaccination series
 Not recommended for all children, but is recommended for some children based on increased risk for or severe outcomes from disease
 Recommended for all age-eligible children, and additional doses may be necessary based on medical condition or other indications. See Notes.
 Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
 Contraindicated or not recommended *Vaccinate after pregnancy, if indicated
 No Guidance/ Not Applicable

a. For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization, "Altered Immunocompetence," at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html and Table 4-1 (footnote J) at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html.
 b. Severe Combined Immunodeficiency
c. LAIV4 contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months

Notes Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

For vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2024.

Additional information

- For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥ 4 months are determined by calendar months.
- Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
- Vaccine doses administered ≤ 4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥ 5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age appropriate. **The repeat dose should be spaced after the invalid dose by the recommended minimum interval.** For further details, see Table 3-2, Recommended and minimum ages and intervals between vaccine doses, in *General Best Practice Guidelines for Immunization* at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
- Information on travel vaccination requirements and recommendations is available at www.cdc.gov/travel/.
- For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in *General Best Practice Guidelines for Immunization* at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html, and Immunization in Special Clinical Circumstances (In: Kimberlin DW, Barnett ED, Lynfield Ruth, Sawyer MH, eds. *Red Book: 2021–2024 Report of the Committee on Infectious Diseases*. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021:72–86).
- For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
- The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All vaccines included in the child and adolescent vaccine schedule are covered by VICP except dengue, PPSV23, RSV, Mpox and COVID-19 vaccines. Mpox and COVID-19 vaccines are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

COVID-19 vaccination

(minimum age: 6 months [Moderna and Pfizer-BioNTech COVID-19 vaccines], 12 years [Novavax COVID-19 Vaccine])

Routine vaccination

Age 6 months–4 years

- Unvaccinated:**
 - 2-dose series of updated (2023–2024 Formula) Moderna at 0, 4–8 weeks
 - 3-dose series of updated (2023–2024 Formula) Pfizer-BioNTech at 0, 3–8, 11–16 weeks
- Previously vaccinated* with 1 dose of any Moderna:** 1 dose of updated (2023–2024 Formula) Moderna 4–8 weeks after the most recent dose.
- Previously vaccinated* with 2 or more doses of any Moderna:** 1 dose of updated (2023–2024 Formula) Moderna at least 8 weeks after the most recent dose.
- Previously vaccinated* with 1 dose of any Pfizer-BioNTech:** 2-dose series of updated (2023–2024 Formula) Pfizer-BioNTech at 0, 8 weeks (minimum interval between previous Pfizer-BioNTech and dose 1: 3–8 weeks).
- Previously vaccinated* with 2 or more doses of any Pfizer-BioNTech:** 1 dose of updated (2023–2024 Formula) Pfizer-BioNTech at least 8 weeks after the most recent dose.

Age 5–11 years

- Unvaccinated:** 1 dose of updated (2023–2024 Formula) Moderna or Pfizer-BioNTech vaccine.
- Previously vaccinated* with 1 or more doses of Moderna or Pfizer-BioNTech:** 1 dose of updated (2023–2024 Formula) Moderna or Pfizer-BioNTech at least 8 weeks after the most recent dose.

Age 12–18 years

- Unvaccinated:**
 - 1 dose of updated (2023–2024 Formula) Moderna or Pfizer-BioNTech vaccine
 - 2-dose series of updated (2023–2024 Formula) Novavax at 0, 3–8 weeks
- Previously vaccinated* with any COVID-19 vaccine(s):** 1 dose of any updated (2023–2024 Formula) COVID-19 vaccine at least 8 weeks after the most recent dose.

Special situations

Persons who are moderately or severely immunocompromised**

Age 6 months–4 years

- Unvaccinated:**
 - 3-dose series of updated (2023–2024 Formula) Moderna at 0, 4, 8 weeks
 - 3-dose series of updated (2023–2024 Formula) Pfizer-BioNTech at 0, 3, 11 weeks.
- Previously vaccinated* with 1 dose of any Moderna:** 2-dose series of updated (2023–2024 Formula) Moderna at 0, 4 weeks (minimum interval between previous Moderna and dose 1: 4 weeks).
- Previously vaccinated* with 2 doses of any Moderna:** 1 dose of updated (2023–2024 Formula) Moderna at least 4 weeks after the most recent dose.
- Previously vaccinated* with 3 or more doses of any Moderna:** 1 dose of updated (2023–2024 Formula) Moderna at least 8 weeks after the most recent dose.
- Previously vaccinated* with 1 dose of any Pfizer-BioNTech:** 2-dose series of updated (2023–2024 Formula) Pfizer-BioNTech at 0, 8 weeks (minimum interval between previous Pfizer-BioNTech and dose 1: 3 weeks).
- Previously vaccinated* with 2 or more doses of any Pfizer-BioNTech:** 1 dose of updated (2023–2024 Formula) Pfizer-BioNTech at least 8 weeks after the most recent dose.

Age 5–11 years

- Unvaccinated:**
 - 3-dose series of updated (2023–2024 Formula) Moderna at 0, 4, 8 weeks
 - 3-dose series updated (2023–2024 Formula) Pfizer-BioNTech at 0, 3, 7 weeks.
- Previously vaccinated* with 1 dose of any Moderna:** 2-dose series of updated (2023–2024 Formula) Moderna at 0, 4 weeks (minimum interval between previous Moderna and dose 1: 4 weeks).
- Previously vaccinated* with 2 doses of any Moderna:** 1 dose of updated (2023–2024 Formula) Moderna at least 4 weeks after the most recent dose.
- Previously vaccinated* with 1 dose of any Pfizer-BioNTech:** 2-dose series of updated (2023–2024 Formula) Pfizer-BioNTech at 0, 4 weeks (minimum interval between previous Pfizer-BioNTech and dose 1: 3 weeks)
- Previously vaccinated* with 2 doses of any Pfizer-BioNTech:** 1 dose of 2023–2024 Pfizer-BioNTech at least 4 weeks after the most recent dose.

Notes Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

- **Previously vaccinated* with 3 or more doses of any Moderna or Pfizer-BioNTech:** 1 dose of updated (2023–2024 Formula) Moderna or Pfizer-BioNTech at least 8 weeks after the most recent dose.

Age 12–18 years

Unvaccinated:

- 3-dose series of updated (2023–2024 Formula) Moderna at 0, 4, 8 weeks
- 3-dose series of updated (2023–2024 Formula) Pfizer-BioNTech at 0, 3, 7 weeks
- 2-dose series of updated (2023–2024 Formula) Novavax at 0, 3 weeks

Previously vaccinated* with 1 dose of any Moderna:

- 2-dose series of updated (2023–2024 Formula) Moderna at 0, 4 weeks (minimum interval between previous Moderna dose and dose 1: 4 weeks).

Previously vaccinated* with 2 doses of any Moderna:

- 1 dose of updated (2023–2024 Formula) Moderna at least 4 weeks after the most recent dose.

Previously vaccinated* with 1 dose of any Pfizer-BioNTech:

- 2-dose series of updated (2023–2024 Formula) Pfizer-BioNTech at 0, 4 weeks (minimum interval between previous Pfizer-BioNTech dose and dose 1: 3 weeks).

Previously vaccinated* with 2 doses of any Pfizer-BioNTech:

- 1 dose of updated (2023–2024 Formula) Pfizer-BioNTech at least 4 weeks after the most recent dose.

Previously vaccinated* with 3 or more doses of any Moderna or Pfizer-BioNTech:

- 1 dose of any updated (2023–2024 Formula) COVID-19 vaccine at least 8 weeks after the most recent dose.

Previously vaccinated* with 1 or more doses of Janssen or Novavax or with or without dose(s) of any Original monovalent or bivalent COVID-19 vaccine:

- 1 dose of any updated (2023–2024 Formula) COVID-19 vaccine at least 8 weeks after the most recent dose.

There is no preferential recommendation for the use of one COVID-19 vaccine over another when more than one recommended age-appropriate vaccine is available.

Administer an age-appropriate COVID-19 vaccine product for each dose. For information about transition from age 4 years to age 5 years or age 11 years to age 12 years during COVID-19 vaccination series, see Tables 1 and 2 at www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html# covid-vaccines.

Current COVID-19 schedule and dosage formulation available at www.cdc.gov/covidschedule. For more information on Emergency Use Authorization (EUA) indications for COVID-19 vaccines, see www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines

***Note:** Previously vaccinated is defined as having received any Original monovalent or bivalent COVID-19 vaccine (Janssen, Moderna, Novavax, Pfizer-BioNTech) prior to the updated 2023–2024 formulation.

****Note:** Persons who are moderately or severely immunocompromised have the option to receive one additional dose of updated (2023–2024 Formula) COVID-19 vaccine at least 2 months following the last recommended updated (2023–2024 Formula) COVID-19 vaccine dose. Further additional updated (2023–2024 Formula) COVID-19 vaccine dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last updated (2023–2024 Formula) COVID-19 vaccine dose. Moderately or severely immunocompromised children 6 months–4 years of age should receive homologous updated (2023–2024 Formula) mRNA vaccine dose(s) if they receive additional doses.

Dengue vaccination (minimum age: 9 years)

Routine vaccination

- Age 9–16 years living in areas with endemic dengue **AND** have laboratory confirmation of previous dengue infection
 - 3-dose series administered at 0, 6, and 12 months
- Endemic areas include Puerto Rico, American Samoa, US Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, and the Republic of Palau. For updated guidance on dengue endemic areas and pre-vaccination laboratory testing see www.cdc.gov/mmwr/volumes/70/rr/rr7006a1.htm?s_cid=rr7006a1_w and www.cdc.gov/dengue/vaccine/hcp/index.html
- Dengue vaccine should not be administered to children traveling to or visiting endemic dengue areas.

Diphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks [4 years for Kinrix® or Quadracel®])

Routine vaccination

- 5-dose series (3-dose primary series at age 2, 4, and 6 months, followed by a booster doses at ages 15–18 months and 4–6 years

- **Prospectively:** Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
- **Retrospectively:** A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3.

Catch-up vaccination

- Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
- For other catch-up guidance, see Table 2.

Special situations

- **Wound management** in children less than age 7 years with history of 3 or more doses of tetanus-toxoid-containing vaccine: For all wounds except clean and minor wounds, administer DTaP if more than 5 years since last dose of tetanus-toxoid-containing vaccine. For detailed information, see www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm.

Haemophilus influenzae type b vaccination (minimum age: 6 weeks)

Routine vaccination

- **ActHIB®, Hiberix®, Pentacel®, or Vaxelis®:** 4-dose series (3-dose primary series at age 2, 4, and 6 months, followed by a booster dose* at age 12–15 months)
 - *Vaxelis® is not recommended for use as a booster dose. A different Hib-containing vaccine should be used for the booster dose.
- **PedvaxHIB®:** 3-dose series (2-dose primary series at age 2 and 4 months, followed by a booster dose at age 12–15 months)

Catch-up vaccination

- **Dose 1 at age 7–11 months:** Administer dose 2 at least 4 weeks later and dose 3 (final dose) at age 12–15 months or 8 weeks after dose 2 (whichever is later).
- **Dose 1 at age 12–14 months:** Administer dose 2 (final dose) at least 8 weeks after dose 1.
- **Dose 1 before age 12 months and dose 2 before age 15 months:** Administer dose 3 (final dose) at least 8 weeks after dose 2.
- **2 doses of PedvaxHIB® before age 12 months:** Administer dose 3 (final dose) at age 12–59 months and at least 8 weeks after dose 2.
- **1 dose administered at age 15 months or older:** No further doses needed
- **Unvaccinated at age 15–59 months:** Administer 1 dose.

Notes Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

- **Previously unvaccinated children age 60 months or older who are not considered high risk:** Do not require catch-up vaccination

For other catch-up guidance, see Table 2. Vaxelis® can be used for catch-up vaccination in children less than age 5 years. Follow the catch-up schedule even if Vaxelis® is used for one or more doses. For detailed information on use of Vaxelis® see www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm.

Special situations

- **Chemotherapy or radiation treatment: Age 12–59 months**

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion.

- **Hematopoietic stem cell transplant (HSCT):**

- 3-dose series 4 weeks apart starting 6 to 12 months after successful transplant, regardless of Hib vaccination history

- **Anatomic or functional asplenia (including sickle cell disease):**

Age 12–59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Unvaccinated* persons age 5 years or older

- 1 dose

- **Elective splenectomy:**

Unvaccinated* persons age 15 months or older

- 1 dose (preferably at least 14 days before procedure)

- **HIV infection:**

Age 12–59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Unvaccinated* persons age 5–18 years

- 1 dose

- **Immunoglobulin deficiency, early component complement deficiency:**

Age 12–59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart

- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

*Unvaccinated = Less than routine series (through age 14 months) **OR** no doses (age 15 months or older)

Hepatitis A vaccination (minimum age: 12 months for routine vaccination)

Routine vaccination

- 2-dose series (minimum interval: 6 months) at age 12–23 months

Catch-up vaccination

- Unvaccinated persons through age 18 years should complete a 2-dose series (minimum interval: 6 months).
- Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.
- Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, **Twinrix**®, as a 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).

International travel

- Persons traveling to or working in countries with high or intermediate endemic hepatitis A (www.cdc.gov/travel/):
 - **Infants age 6–11 months:** 1 dose before departure; revaccinate with 2 doses (separated by at least 6 months) between age 12–23 months.
 - **Unvaccinated age 12 months or older:** Administer dose 1 as soon as travel is considered.

Hepatitis B vaccination (minimum age: birth)

Routine vaccination

- 3-dose series at age 0, 1–2, 6–18 months (**use monovalent HepB vaccine for doses administered before age 6 weeks**)
 - Birth weight $\geq 2,000$ grams: 1 dose within 24 hours of birth if medically stable
 - Birth weight $< 2,000$ grams: 1 dose at chronological age 1 month or hospital discharge (whichever is earlier and even if weight is still $< 2,000$ grams).
- Infants who did not receive a birth dose should begin the series as soon as possible (see Table 2 for minimum intervals).
- Administration of 4 doses is permitted when a combination vaccine containing HepB is used after the birth dose.
- **Minimum intervals (see Table 2):** when 4 doses are administered, substitute “dose 4” for “dose 3” in these calculations

- **Final (3rd or 4th) dose:** age 6–18 months (**minimum age 24 weeks**)

- **Mother is HBsAg-positive**

- **Birth dose (monovalent HepB vaccine only):** administer **HepB vaccine** and **hepatitis B immune globulin (HBIG)** (in separate limbs) within 12 hours of birth, regardless of birth weight.
- **Birth weight < 2000 grams:** administer 3 additional doses of HepB vaccine beginning at age 1 month (total of 4 doses)
- **Final (3rd or 4th) dose:** administer at age 6 months (**minimum age 24 weeks**)
- Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose. Do not test before age 9 months.

- **Mother is HBsAg-unknown**

If other evidence suggestive of maternal hepatitis B infection exists (e.g., presence of HBV DNA, HBsAg-positive, or mother known to have chronic hepatitis B infection), manage infant as if mother is HBsAg-positive

- **Birth dose (monovalent HepB vaccine only):**

- Birth weight $\geq 2,000$ grams: administer **HepB vaccine** within 12 hours of birth. Determine mother’s HBsAg status as soon as possible. If mother is determined to be HBsAg-positive, administer **HBIG** as soon as possible (in separate limb), but no later than 7 days of age.
- Birth weight $< 2,000$ grams: administer **HepB vaccine** and **HBIG** (in separate limbs) within 12 hours of birth. Administer 3 additional doses of **HepB vaccine** beginning at age 1 month (total of 4 doses)

- **Final (3rd or 4th) dose:** administer at age 6 months (**minimum age 24 weeks**)

- If mother is determined to be HBsAg-positive or if status remains unknown, test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose. Do not test before age 9 months.

Catch-up vaccination

- Unvaccinated persons should complete a 3-dose series at 0, 1–2, 6 months. See Table 2 for minimum intervals
- Adolescents age 11–15 years may use an alternative 2-dose schedule with at least 4 months between doses (adult formulation **Recombivax HB**® only).
- Adolescents age 18 years may receive:
 - **HepLisav-B**®: 2-dose series at least 4 weeks apart
 - **PreHevrio**®: 3-dose series at 0, 1, and 6 months
 - Combined HepA and HepB vaccine, **Twinrix**®: 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).

Special situations

- Revaccination is not generally recommended for persons with a normal immune status who were vaccinated as infants, children, adolescents, or adults.
- **Post-vaccination serology testing and revaccination** (if anti-HBs <10mIU/mL) is recommended for certain populations, including:
 - Infants born to HBsAg-positive mothers
 - Persons who are predialysis or on maintenance dialysis
 - Other immunocompromised persons
 - For detailed revaccination recommendations, see www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html.

Note: Heplisav-B and PreHevbrio are not recommended in pregnancy due to lack of safety data in pregnant persons

Human papillomavirus vaccination (minimum age: 9 years)

Routine and catch-up vaccination

- HPV vaccination routinely recommended at **age 11–12 years (can start at age 9 years)** and catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated
- 2- or 3-dose series depending on age at initial vaccination:
 - **Age 9–14 years at initial vaccination:** 2-dose series at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon)
 - **Age 15 years or older at initial vaccination:** 3-dose series at 0, 1–2 months, 6 months (minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 3: 5 months; repeat dose if administered too soon)
- No additional dose recommended when any HPV vaccine series **of any valency** has been completed using recommended dosing intervals.

Special situations

- **Immunocompromising conditions, including HIV infection:** 3-dose series, even for those who initiate vaccination at age 9 through 14 years.
- **History of sexual abuse or assault:** Start at age 9 years
- **Pregnancy:** Pregnancy testing not needed before vaccination; HPV vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant

Influenza vaccination

(minimum age: 6 months [IIV], 2 years [LAIV4], 18 years [recombinant influenza vaccine, RIV4])

Routine vaccination

- Use any influenza vaccine appropriate for age and health status annually:
 - **Age 6 months–8 years** who have received **fewer** than 2 influenza vaccine doses before July 1, 2023, or whose influenza vaccination history is unknown: 2 doses, separated by at least 4 weeks. Administer dose 2 even if the child turns 9 years between receipt of dose 1 and dose 2.
 - **Age 6 months–8 years** who have received **at least 2** influenza vaccine doses before July 1, 2023: 1 dose
 - **Age 9 years or older:** 1 dose
- For the 2023–2024 season, see www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm.
- For the 2024–25 season, see the 2024–25 ACIP influenza vaccine recommendations.

Special situations

- **Close contacts (e.g., household contacts) of severely immunosuppressed persons who require a protected environment:** should not receive LAIV4. If LAIV4 is given, they should avoid contact with for such immunosuppressed persons for 7 days after vaccination.

Note: Persons with an egg allergy can receive any influenza vaccine (egg-based and non-egg-based) appropriate for age and health status.

Measles, mumps, and rubella vaccination (minimum age: 12 months for routine vaccination)

Routine vaccination

- 2-dose series at age 12–15 months, age 4–6 years
- MMR or MMRV* may be administered

Note: For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV* may be used if parents or caregivers express a preference.

Catch-up vaccination

- Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart*
- The maximum age for use of MMRV* is 12 years.

Special situations

International travel

- **Infants age 6–11 months:** 1 dose before departure; revaccinate with 2-dose series at age 12–15 months (12 months for children in high-risk areas) and dose 2 as early as 4 weeks later.*
- **Unvaccinated children age 12 months or older:** 2-dose series at least 4 weeks apart before departure*

- In mumps outbreak settings, for information about additional doses of MMR (including 3rd dose of MMR), see www.cdc.gov/mmwr/volumes/67/wr/mm6701a7.htm

***Note:** If MMRV is used, the minimum interval between MMRV doses is 3 months

Meningococcal serogroup A,C,W,Y vaccination (minimum age: 2 months [MenACWY-CRM, Menveo], 2 years [MenACWY-TT, MenQuadfi]), 10 years [MenACWY-TT/MenB-FHbp, Penbraya])

Routine vaccination

- 2-dose series at age 11–12 years; 16 years

Catch-up vaccination

- Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks)
- Age 16–18 years: 1 dose

Special situations

Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:

Menveo**

- Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6, and 12 months)
- Dose 1 at age 3–6 months: 3- or 4-dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
- Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart

MenQuadfi®

- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart

Notes Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

Travel to countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj (www.cdc.gov/travel/):

- Children less than age 24 months:
 - **Menveo^{®*} (age 2–23 months)**
 - Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6, and 12 months)
 - Dose 1 at age 3–6 months: 3- or 4-dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
 - Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
- Children age 2 years or older: 1 dose Menveo^{®*} or MenQuadfi[®]

First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) or military recruits:

- 1 dose **Menveo^{®*}** or **MenQuadfi[®]**

Adolescent vaccination of children who received MenACWY prior to age 10 years:

- **Children for whom boosters are recommended** because of an ongoing increased risk of meningococcal disease (e.g., those with complement component deficiency, HIV, or asplenia): Follow the booster schedule for persons at increased risk.
- **Children for whom boosters are not recommended** (e.g., a healthy child who received a single dose for travel to a country where meningococcal disease is endemic): Administer MenACWY according to the recommended adolescent schedule with dose 1 at age 11–12 years and dose 2 at age 16 years.

**Menveo has two formulations: lyophilized and liquid. The liquid formulation should not be used before age 10 years. See www.cdc.gov/vaccines/vpd/mening/downloads/menveo-single-vial-presentation.pdf.*

Note: For MenACWY **booster dose recommendations** for groups listed under “Special situations” and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

Children age 10 years or older may receive a single dose of Penbraya[™] as an alternative to separate administration of MenACWY and MenB when both vaccines would be given on the same clinic day (see “Meningococcal serogroup B vaccination” section below for more information).

Meningococcal serogroup B vaccination (minimum age: 10 years [MenB-4C, Bexsero[®]; MenB-FHbp, Trumenba[®]; MenACWY-TT/MenB-FHbp, Penbraya[™]])

Shared clinical decision-making

- **Adolescents not at increased risk** age 16–23 years (preferred age 16–18 years) based on shared clinical decision-making:
 - **Bexsero[®]:** 2-dose series at least 1 month apart
 - **Trumenba[®]:** 2-dose series at least 6 months apart (if dose 2 is administered earlier than 6 months, administer a 3rd dose at least 4 months after dose 2)

For additional information on shared clinical decision-making for MenB, see www.cdc.gov/vaccines/hcp/admin/downloads/isd-job-aid-scdm-mening-b-shared-clinical-decision-making.pdf

Special situations

Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:

- **Bexsero[®]:** 2-dose series at least 1 month apart
- **Trumenba[®]:** 3-dose series at 0, 1–2, 6 months (if dose 2 was administered at least 6 months after dose 1, dose 3 not needed; if dose 3 is administered earlier than 4 months after dose 2, a 4th dose should be administered at least 4 months after dose 3)

Note: **Bexsero[®]** and **Trumenba[®]** are not interchangeable; the same product should be used for all doses in a series.

For MenB **booster dose recommendations** for groups listed under “Special situations” and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

Children age 10 years or older may receive a dose of Penbraya[™] as an alternative to separate administration of MenACWY and MenB when both vaccines would be given on the same clinic day. For age-eligible children not at increased risk, if Penbraya[™] is used for dose 1 MenB, MenB-FHbp (Trumenba) should be administered for dose 2 MenB. For age-eligible children at increased risk of meningococcal disease, Penbraya[™] may be used for additional MenACWY and MenB doses (including booster doses) if both would be given on the same clinic day **and** at least 6 months have elapsed since most recent Penbraya[™] dose.

Mpox vaccination (minimum age: 18 years [Jynneos[®]])

Special situations

- **Age 18 years and at risk for Mpox infection:** 2-dose series, 28 days apart.

Risk factors for Mpox infection include:

- Persons who are gay, bisexual, and other MSM, transgender or nonbinary people who in the past 6 months have had:
 - A new diagnosis of at least 1 sexually transmitted disease
 - More than 1 sex partner
 - Sex at a commercial sex venue
 - Sex in association with a large public event in a geographic area where Mpox transmission is occurring
- Persons who are sexual partners of the persons described above
- Persons who anticipate experiencing any of the situations described above

- **Pregnancy:** There is currently no ACIP recommendation for Jynneos use in pregnancy due to lack of safety data in pregnant persons. Pregnant persons with any risk factor described above may receive Jynneos.

For detailed information, see: www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/04-MPOX-Rao-508.pdf

Pneumococcal vaccination (minimum age: 6 weeks [PCV15], [PCV 20]; 2 years [PPSV23])

Routine vaccination with PCV

- 4-dose series at 2, 4, 6, 12–15 months

Catch-up vaccination with PCV

- Healthy children ages 2–4 years with any incomplete* PCV series: 1 dose PCV
- For other catch-up guidance, see Table 2.

Note: For children **without** risk conditions, PCV20 is not indicated if they have received 4 doses of PCV13 or PCV15 or another age appropriate complete PCV series.

Special situations

Children and adolescents with cerebrospinal fluid leak; chronic heart disease; chronic kidney disease (excluding maintenance dialysis and nephrotic syndrome); chronic liver disease; chronic lung disease (including moderate persistent or severe persistent asthma); cochlear implant; or diabetes mellitus:

Age 2–5 years

- Any incomplete* PCV series with:
 - 3 PCV doses: 1 dose PCV (at least 8 weeks after the most recent PCV dose)
 - Less than 3 PCV doses: 2 doses PCV (at least 8 weeks after the most recent dose and administered at least 8 weeks apart)
- Completed recommended PCV series but have not received PPSV23
 - Previously received at least 1 dose of PCV20: no further PCV or PPSV23 doses needed
 - Not previously received PCV20: administer 1 dose PCV20 OR 1 dose PPSV23 administer at least 8 weeks after the most recent PCV dose.

Age 6–18 years

- Not previously received any dose of PCV13, PCV15, or PCV20: administer 1 dose of PCV15 or PCV20. If PCV15 is used and no previous receipt of PPSV23, administer 1 dose of PPSV23 at least 8 weeks after the PCV15 dose.**
- Received PCV before age 6 years but have not received PPSV23
 - Previously received at least 1 dose of PCV20: no further PCV or PPSV23 doses needed
 - Not previously received PCV20: 1 dose PCV20 OR 1 dose PPSV23 administer at least 8 weeks after the most recent PCV dose.
- Received PCV13 only at or after age 6 years: administer 1 dose PCV20 OR 1 dose PPSV23 at least 8 weeks after the most recent PCV13 dose.
- Received 1 dose PCV13 and 1 dose PPSV23 at or after age 6 years: no further doses of any PCV or PPSV23 indicated.

Children and adolescents on maintenance dialysis, or with immunocompromising conditions such as nephrotic syndrome; congenital or acquired asplenia or splenic dysfunction; congenital or acquired immunodeficiencies; diseases and conditions treated with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and solid organ transplant; HIV infection; or sickle cell disease or other hemoglobinopathies:

Age 2–5 years

- Any incomplete* PCV series:
 - 3 PCV doses: 1 dose PCV (at least 8 weeks after the most recent PCV dose)
 - Less than 3 PCV doses: 2 doses PCV (at least 8 weeks after the most recent dose and administered at least 8 weeks apart)
- Completed recommended PCV series but have not received PPSV23
 - Previously received at least 1 dose of PCV20: no further PCV or PPSV23 doses needed
 - Not previously received PCV20: administer 1 dose PCV20 OR 1 dose PPSV23 at least 8 weeks after the most recent PCV dose. If PPSV23 is used, administer 1 dose of PCV20 or dose 2 PPSV23 at least 5 years after dose 1 PPSV23.

Age 6–18 years

- Not previously received any dose of PCV13, PCV15, or PCV20: administer 1 dose of PCV15 or 1 dose of PCV20. If PCV15 is used and no previous receipt of PPSV23, administer 1 dose of PPSV23 at least 8 weeks after the PCV15 dose.**
- Received PCV before age 6 years but have not received PPSV23
 - Previously received at least 1 dose of PCV20: no additional dose of PCV or PPSV23
 - Not previously received PCV20: administer 1 dose PCV20 OR 1 dose PPSV23 at least 8 weeks after the most recent PCV dose. If PPSV23 is used, administer either PCV20 or dose 2 PPSV23 at least 5 years after dose 1 PPSV23.
- Received PCV13 only at or after age 6 years: administer 1 dose PCV20 OR 1 dose PPSV23 at least 8 weeks after the most recent PCV13 dose. If PPSV23 is used, administer 1 dose of PCV20 or dose 2 PPSV23 at least 5 years after dose 1 PPSV23.
- Received 1 dose PCV13 and 1 dose PPSV23 at or after age 6 years: administer 1 dose PCV20 OR 1 dose PPSV23 at least 8 weeks after the most recent PCV13 dose and at least 5 years after dose 1 PPSV23.

**Incomplete series* = Not having received all doses in either the recommended series or an age-appropriate catch-up series. See Table 2 in ACIP pneumococcal recommendations at stacks.cdc.gov/view/cdc/133252

***When both PCV15 and PPSV23 are indicated, administer all doses of PCV15 first. PCV15 and PPSV23 should not be administered during the same visit.*

For guidance on determining which pneumococcal vaccines a patient needs and when, please refer to the mobile app, which can be downloaded here: www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html

Poliovirus vaccination (minimum age: 6 weeks)

Routine vaccination

- 4-dose series at ages 2, 4, 6–18 months, 4–6 years; administer the final dose on or after age 4 years and at least 6 months after the previous dose.
- 4 or more doses of IPV can be administered before age 4 years when a combination vaccine containing IPV is used. However, a dose is still recommended on or after age 4 years and at least 6 months after the previous dose.

Catch-up vaccination

- In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
- **Adolescents age 18 years known or suspected to be unvaccinated or incompletely vaccinated:** administer remaining doses (1, 2, or 3 IPV doses) to complete a 3-dose primary series.* Unless there are specific reasons to believe they were not vaccinated, most persons aged 18 years or older born and raised in the United States can assume they were vaccinated against polio as children.

Series containing oral poliovirus vaccine (OPV), either mixed OPV-IPV or OPV-only series:

- Total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. See www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm?s_cid=mm6601a6_w.
- Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements.
 - Doses of OPV administered before April 1, 2016, should be counted (unless specifically noted as administered during a campaign).
 - Doses of OPV administered on or after April 1, 2016, should not be counted.
 - For guidance to assess doses documented as “OPV;” see www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s_cid=mm6606a7_w.
- For other catch-up guidance, see Table 2.

Special situations

- **Adolescents aged 18 years at increased risk of exposure to poliovirus and completed primary series***: may administer one lifetime IPV booster

***Note**: Complete primary series consist of at least 3 doses of IPV or trivalent oral poliovirus vaccine (tOPV) in any combination.

For detailed information, see: www.cdc.gov/vaccines/vpd/polio/hcp/recommendations.html

Respiratory syncytial virus immunization (minimum age: birth [Nirsevimab, RSV-mAb (Beyfortus™)])

Routine immunization

- **Infants born October – March in most of the continental United States***

- Mother did not receive RSV vaccine OR mother's RSV vaccination status is unknown: administer 1 dose nirsevimab within 1 week of birth in hospital or outpatient setting
- Mother received RSV vaccine **less than 14 days** prior to delivery: administer 1 dose nirsevimab within 1 week of birth in hospital or outpatient setting

- Mother received RSV vaccine **at least 14 days** prior to delivery: nirsevimab not needed but can be considered in rare circumstances at the discretion of healthcare providers (see special populations and situations at www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html)

- **Infants born April–September in most of the continental United States***

- Mother did not receive RSV vaccine OR mother's RSV vaccination status is unknown: administer 1 dose nirsevimab shortly before start of RSV season*
- Mother received RSV vaccine **less than 14 days** prior to delivery: administer 1 dose nirsevimab shortly before start of RSV season*
- Mother received RSV vaccine **at least 14 days** prior to delivery: nirsevimab not needed but can be considered in rare circumstances at the discretion of healthcare providers(see special populations and situations at www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html)

Infants with prolonged birth hospitalization** (e.g., for prematurity) discharged October through March should be immunized shortly before or promptly after discharge.

Special situations

- **Ages 8–19 months with chronic lung disease of prematurity requiring medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season; severe immunocompromise; cystic fibrosis with either weight for length <10th percentile or manifestation of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable)**:**

- 1 dose nirsevimab shortly before start of second RSV season*

- **Ages 8–19 months who are American Indian or Alaska Native:**

- 1 dose nirsevimab shortly before start of second RSV season*

- **Age-eligible and undergoing cardiac surgery with cardiopulmonary bypass**:** 1 additional dose of nirsevimab after surgery. For additional details see special populations and situations at www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html

***Note**: While the timing of the onset and duration of RSV season may vary, nirsevimab may be administered October through March in most of the continental United States. Providers in jurisdictions with RSV seasonality that differs from most of the continental United States (e.g., Alaska, jurisdiction with tropical climate) should follow guidance from public health authorities (e.g., CDC, health departments) or regional medical centers on timing of administration based on local RSV seasonality. Although optimal timing of administration is just before the start of the RSV season, nirsevimab may also be administered during the RSV season to infants and children who are age-eligible.

****Note**: Nirsevimab can be administered to children who are eligible to receive palivizumab. Children who have received nirsevimab should not receive palivizumab for the same RSV season.

For further guidance, see www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm and www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html

Respiratory syncytial virus vaccination (RSV [Abrysvo™])

Routine vaccination

- **Pregnant at 32 weeks 0 days through 36 weeks and 6 days gestation from September through January in most of the continental United States***: 1 dose RSV vaccine (Abrysvo™). Administer RSV vaccine regardless of previous RSV infection.

- Either maternal RSV vaccination or infant immunization with nirsevimab (RSV monoclonal antibody) is recommended to prevent respiratory syncytial virus lower respiratory tract infection in infants.

- **All other pregnant persons**: RSV vaccine not recommended.

There is currently no ACIP recommendation for RSV vaccination in subsequent pregnancies. No data are available to inform whether additional doses are needed in later pregnancies.

***Note**: Providers in jurisdictions with RSV seasonality that differs from most of the continental United States (e.g., Alaska, jurisdiction with tropical climate) should follow guidance from public health authorities (e.g., CDC, health departments) or regional medical centers on timing of administration based on local RSV seasonality.

Rotavirus vaccination (minimum age: 6 weeks)

Routine vaccination

- **Rotarix®**: 2-dose series at age 2 and 4 months
- **RotaTeq®**: 3-dose series at age 2, 4, and 6 months
- If any dose in the series is either **RotaTeq®** or unknown, default to 3-dose series.

Catch-up vaccination

- Do not start the series on or after age 15 weeks, 0 days.
- The maximum age for the final dose is 8 months, 0 days.
- For other catch-up guidance, see Table 2.

Tetanus, diphtheria, and pertussis (Tdap) vaccination

(minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination)

Routine vaccination

- **Age 11–12 years:** 1 dose Tdap (adolescent booster)
- **Pregnancy:** 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–36.

Note: Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.

Catch-up vaccination

- **Age 13–18 years who have not received Tdap:** 1 dose Tdap (adolescent booster)
- **Age 7–18 years not fully vaccinated* with DTaP:** 1 dose Tdap as part of the catch-up series (preferably the first dose); if additional doses are needed, use Td or Tdap.
- **Tdap administered at age 7–10 years:**
 - **Age 7–9 years** who receive Tdap should receive the adolescent Tdap booster dose at age 11–12 years.
 - **Age 10 years** who receive Tdap do not need the adolescent Tdap booster dose at age 11–12 years.
- **DTaP inadvertently administered on or after age 7 years:**
 - **Age 7–9 years:** DTaP may count as part of catch-up series. Administer adolescent Tdap booster dose at age 11–12 years.
 - **Age 10–18 years:** Count dose of DTaP as the adolescent Tdap booster dose.
- For other catch-up guidance, see Table 2.

Special situations

- **Wound management** in persons age 7 years or older with history of 3 or more doses of tetanus-toxoid-containing vaccine: For clean and minor wounds, administer Tdap or Td if more than 10 years since last dose of tetanus-toxoid-containing vaccine; for all other wounds, administer Tdap or Td if more than 5 years since last dose of tetanus-toxoid-containing vaccine. Tdap is preferred for persons age 11 years or older who have not previously received Tdap or whose Tdap history is unknown. If a tetanus-toxoid-containing vaccine is indicated for a pregnant adolescent, use Tdap.
- For detailed information, see www.cdc.gov/mmwr/volumes/69/wr/mm6903a5.htm.

*Fully vaccinated = 5 valid doses of DTaP OR 4 valid doses of DTaP if dose 4 was administered at age 4 years or older

Varicella vaccination (minimum age: 12 months)

Routine vaccination

- 2-dose series at age 12–15 months, 4–6 years
- VAR or MMRV may be administered*
- Dose 2 may be administered as early as 3 months after dose 1 (a dose inadvertently administered after at least 4 weeks may be counted as valid)

***Note:** For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.

Catch-up vaccination

- Ensure persons age 7–18 years without evidence of immunity (see *MMWR* at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have a 2-dose series:
 - **Age 7–12 years:** Routine interval: 3 months (a dose inadvertently administered after at least 4 weeks may be counted as valid)
 - **Age 13 years and older:** Routine interval: 4–8 weeks (minimum interval: 4 weeks)
 - The maximum age for use of *MMRV* is 12 years.

Guide to Contraindications and Precautions to Commonly Used Vaccines

Adapted from Table 4-1 in *Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions, Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season* | MMWR (cdc.gov), *Contraindications and Precautions for COVID-19 Vaccination*, and *Contraindications and Precautions for JYNNEOS Vaccination*

Vaccines and other Immunizing Agents	Contraindicated or Not Recommended ¹	Precautions ²
COVID-19 mRNA vaccines [Pfizer-BioNTech, Moderna]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of an mRNA COVID-19 vaccine⁴ 	<ul style="list-style-type: none"> Diagnosed non-severe allergy (e.g., urticaria beyond the injection site) to a component of an mRNA COVID-19 vaccine⁴; or non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of an mRNA COVID-19 vaccine Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine Multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A) Moderate or severe acute illness, with or without fever
COVID-19 protein subunit vaccine [Novavax]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of a Novavax COVID-19 vaccine⁴ 	<ul style="list-style-type: none"> Diagnosed non-severe allergy (e.g., urticaria beyond the injection site) to a component of Novavax COVID-19 vaccine⁴; or non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of a Novavax COVID-19 vaccine Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine Multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A) Moderate or severe acute illness, with or without fever
Influenza, egg-based, inactivated injectable (IIV4)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, cclIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Moderate or severe acute illness with or without fever
Influenza, cell culture-based inactivated injectable (ccIIV4) [Flucelvax Quadrivalent]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component³ of ccIIV4 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, recombinant injectable (RIV4) [Flublok Quadrivalent]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component³ of RIV4 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, ccIIV, or LAIV of any valency. If using RIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, live attenuated (LAIV4) [Flumist Quadrivalent]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) Children age 2–4 years with a history of asthma or wheezing Anatomic or functional asplenia Immunocompromised due to any cause including, but not limited to, medications and HIV infection Close contacts or caregivers of severely immunosuppressed persons who require a protected environment Pregnancy Cochlear implant Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear or any other cranial CSF leak Children and adolescents receiving aspirin or salicylate-containing medications Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Asthma in persons age 5 years old or older Persons with underlying medical conditions other than those listed under contraindications that might predispose to complications after wild-type influenza virus infection, e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus) Moderate or severe acute illness with or without fever

- When a contraindication is present, a vaccine should **NOT** be administered. Kroger A, Bahta L, Hunter P. [ACIP General Best Practice Guidelines for Immunization](#).
- When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. [ACIP General Best Practice Guidelines for Immunization](#).
- Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. See [Package inserts for U.S.-licensed vaccines](#).
- See [package inserts](#) and [FDA EUA fact sheets](#) for a full list of vaccine ingredients. mRNA COVID-19 vaccines contain polyethylene glycol (PEG).

Appendix

Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

Vaccines and other Immunizing Agents	Contraindicated or Not Recommended ¹	Precautions ²
Dengue (DEN4CYD)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) Lack of laboratory confirmation of a previous Dengue infection 	<ul style="list-style-type: none"> Pregnancy HIV infection without evidence of severe immunosuppression Moderate or severe acute illness with or without fever
Diphtheria, tetanus, pertussis (DTaP)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For DTaP only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP or DTaP 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after previous dose of tetanus-toxoid-containing vaccine History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid-containing or tetanus-toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid-containing vaccine For DTaP only: Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaP until neurologic status clarified and stabilized Moderate or severe acute illness with or without fever
<i>Haemophilus influenzae</i> type b (Hib)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Less than age 6 weeks 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Hepatitis A (HepA)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ including neomycin 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Hepatitis B (HepB)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ including yeast Pregnancy: <i>Heplisav-B and PreHevbrio are not recommended due to lack of safety data in pregnant persons. Use other hepatitis B vaccines if HepB is indicated⁴.</i> 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Hepatitis A-Hepatitis B vaccine (HepA-HepB) [Twinrix]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ including neomycin and yeast 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Human papillomavirus (HPV)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Pregnancy: <i>HPV vaccination not recommended.</i> 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Measles, mumps, rubella (MMR) Measles, mumps, rubella, and varicella (MMRV)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) Pregnancy Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent 	<ul style="list-style-type: none"> Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product) History of thrombocytopenia or thrombocytopenic purpura Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing Moderate or severe acute illness with or without fever For MMRV only: Personal or family (i.e., sibling or parent) history of seizures of any etiology
Meningococcal ACWY (MenACWY) MenACWY-CRM [Menveo] MenACWY-TT [MenQuadfi]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For Men ACWY-CRM only: severe allergic reaction to any diphtheria toxoid—or CRM197—containing vaccine For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine 	<ul style="list-style-type: none"> For MenACWY-CRM only: Preterm birth if less than age 9 months Moderate or severe acute illness with or without fever
Meningococcal B (MenB) MenB-4C [Bexsero] MenB-FHbp [Trumenba]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	<ul style="list-style-type: none"> Pregnancy For MenB-4C only: Latex sensitivity Moderate or severe acute illness with or without fever
Meningococcal ABCWY (MenACWY-TT/MenB-FHbp) [Penbraya]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe allergic reaction to a tetanus toxoid-containing vaccine 	<ul style="list-style-type: none"> Moderate or severe acute illness, with or without fever
Mpox [Jynneos]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	<ul style="list-style-type: none"> Moderate or severe acute illness, with or without fever
Pneumococcal conjugate (PCV)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid-containing vaccine or its component³ 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Pneumococcal polysaccharide (PPSV23)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Poliovirus vaccine, inactivated (IPV)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	<ul style="list-style-type: none"> Pregnancy Moderate or severe acute illness with or without fever
RSV monoclonal antibody (RSV-mAb)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Respiratory syncytial virus vaccine (RSV)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ 	<ul style="list-style-type: none"> Moderate or severe acute illness with or without fever
Rotavirus (RV) RV1 [Rotarix] RV5 [RotaTeq]	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe combined immunodeficiency (SCID) History of intussusception 	<ul style="list-style-type: none"> Altered immunocompetence other than SCID Chronic gastrointestinal disease RV1 only: Spina bifida or bladder exstrophy Moderate or severe acute illness with or without fever
Tetanus, diphtheria, and acellular pertussis (Tdap) Tetanus, diphtheria (Td)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For Tdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP, DTaP, or Tdap 	<ul style="list-style-type: none"> Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid-containing vaccine History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid-containing or tetanus-toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid-containing vaccine For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized Moderate or severe acute illness with or without fever
Varicella (VAR)	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) Pregnancy Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent 	<ul style="list-style-type: none"> Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product) Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination) Use of aspirin or aspirin-containing products Moderate or severe acute illness with or without fever If using MMRV, see MMR/MMRV for additional precautions

- When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
- When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
- Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states.
- For information on the pregnancy exposure registries for persons who were inadvertently vaccinated with Heplisav-B or PreHevbrio while pregnant, please visit heplisavbpregnancyregistry.com or www.prehevbrio.com/#safety.
- Full prescribing information for BEYFORTUS (nirsevimab-alip) www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf

Addendum

Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

In addition to the recommendations presented in the previous sections of this immunization schedule, ACIP has approved the following recommendations by majority vote since October 26, 2023. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines	Recommendations	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech, Novavax)	<ul style="list-style-type: none">ACIP recommends 2024-2025 COVID-19 vaccines as authorized or approved by FDA in persons ≥ 6 months of age.	June 27, 2024
Influenza	<ul style="list-style-type: none">ACIP reaffirms the recommendation for routine annual influenza vaccination of all persons aged ≥ 6 months who do not have contraindications.ACIP recommends high-dose inactivated (HD-IIV3) and adjuvanted inactivated (aIIV3) influenza vaccines as acceptable options for influenza vaccination of solid organ transplant recipients aged 18 through 64 years who are on immunosuppressive medication regimens, without a preference over other age-appropriate IIV3s or RIV3.	June 27, 2024
Vaxelis (DTaP-IPV-Hib-HepB)	<ul style="list-style-type: none">ACIP recommends DTaP-IPV-Hib-HepB (Vaxelis[®]) should be included with PRP-OMP (PedvaxHIB[®]) in the preferential recommendation for American Indian and Alaska Native infants based on the <i>Haemophilus influenzae</i> type b (Hib) component.	June 26, 2024

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official.

Children age 4 months through 6 years

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. **Always use this table in conjunction with Table 1 and the Notes that follow.**

Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses			
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
Hepatitis B ⓘ	Birth	4 weeks	8 weeks and at least 16 weeks after first dose. Minimum age for the final dose is 24 weeks		
Rotavirus ⓘ	6 weeks Maximum age for first dose is 14 weeks, 6 days.	4 weeks	4 weeks Maximum age for final dose is 8 months, 0 days		
Diphtheria, tetanus, and acellular pertussis ⓘ	6 weeks	4 weeks	4 weeks	6 months	6 months A fifth dose is not necessary if the fourth dose was administered at age 4 years or older and at least 6 months after dose 3

Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses			
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
Haemophilus influenzae type b ⓘ	6 weeks	<p>No further doses needed if first dose was administered at age 15 months or older.</p> <p>4 weeks if first dose was administered before the 1st birthday.</p> <p>8 weeks (as final dose) if first dose was administered at age 12 through 14 months.</p>	<p>No further doses needed if previous dose was administered at age 15 months or older</p> <p>4 weeks If current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRP-T (ActHib[®], Pentacel[®], Hiberix[®]), Vaxelis[®] or unknown</p> <p>8 weeks and age 12 through 59 months (as final dose) if current age is younger than 12 months and first dose was administered at age 7 through 11 months;</p> <p>OR if current age is 12 through 59 months and first dose was administered before the 1st birthday, and second dose was administered at younger than 15 months;</p> <p>OR if both doses were PedvaxHIB[®] and were</p>	<p>8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1st birthday.</p>	

Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses			
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
			administered before the 1 st birthday		
Pneumococcal conjugate ⓘ	6 weeks	<p>No further doses needed for healthy children if first dose was administered at age 24 months or older</p> <p>4 weeks if first dose administered before the 1st birthday</p> <p>8 weeks (as final dose for healthy children) if first dose was administered at the 1st birthday or after</p>	<p>No further doses needed for healthy children if previous dose was administered at age 24 months or older</p> <p>4 weeks if current age is younger than 12 months and previous dose given at <7 months old</p> <p>8 weeks (as final dose for healthy children) if previous dose given between 7-11 months (wait until at least 12 months old);</p> <p>OR</p> <p>if current age is 12 months or older <i>and</i> at least 1 dose was administered before age 12 months</p>	<p>8 weeks (as final dose)</p> <p>This dose is only necessary for children age 12 through 59 months regardless of risk, or age 60 through 71 months with any risk, who received 3 doses before age 12 months.</p>	
Inactivated poliovirus ⓘ	6 weeks	4 weeks	<p>4 weeks if current age is <4 years</p> <p>6 months (as final dose) if current age is 4 years or older</p>	6 months (minimum age 4 years for final dose)	
Measles, mumps, rubella ⓘ	12 months	4 weeks			
Varicella ⓘ	12 months	3 months			

Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses			
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
Hepatitis A ⓘ	12 months	6 months			
Meningococcal ACWY ⓘ	2 months MenACWY-CRM 2 years MenACWY-TT	8 weeks	See notes	See notes	

Children and adolescents age 7 through 18 years

Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses		
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4
Meningococcal ACWY ⓘ	Not Applicable (N/A)	8 weeks		
Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis ⓘ	7 years	4 weeks	4 weeks if first dose of DTaP/DT was administered before the 1 st birthday 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1 st birthday	6 months if first dose of DTaP/DT was administered before the 1 st birthday
Human papillomavirus ⓘ	9 years	Routine dosing intervals are recommended.		
Hepatitis A ⓘ	N/A	6 months		
Hepatitis B ⓘ	N/A	4 weeks	8 weeks and at least 16 weeks after first dose.	

Vaccine	Minimum Age for Dose 1	Minimum Interval Between Doses		
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4
Inactivated poliovirus ⓘ	N/A	4 weeks	6 months A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.	A fourth dose of IPV is indicated if all previous doses were administered at <4 years OR if the third dose was administered <6 months after the second dose.
Measles, mumps, rubella ⓘ	N/A	4 weeks		
Varicella ⓘ	N/A	3 months if younger than age 13 years. 4 weeks if age 13 years or older		
Dengue ⓘ	9 years	6 months	6 months	

To make vaccination recommendations, healthcare providers should:

1. Determine recommended vaccine by age ([Table 1 – By Age](#))
2. Determine recommended interval for catch-up vaccination ([Table 2 – Catch-up](#))
3. Assess need for additional recommended vaccines by medical condition or other indication ([Table 3 – By Medical Indication](#))
4. Review vaccine types, frequencies, intervals, and considerations for special situations ([Notes](#))
5. Review contraindications and precautions for vaccine types ([Appendix](#))
6. Review new or updated ACIP guidance ([Addendum](#))

Recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAP ⓘ), American Academy of Family Physicians (AAFP ⓘ), American College of Obstetricians and Gynecologists (ACOG ⓘ), American College of Nurse-Midwives (ACNM ⓘ), American Academy of Physician Associates (AAPA ⓘ), and National Association of Pediatric Nurse Practitioners (NAPNAP ⓘ).

The comprehensive summary of the ACIP recommended changes made to the child and adolescent immunization schedule can be found in the [January 11, 2024 MMWR](#).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov ⓘ or (800-822-7967)

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.

Helpful information

- [Complete Advisory Committee on Immunization Practices \(ACIP\) recommendations](#)
- [ACIP Shared Clinical Decision-Making Recommendations](#)
- [General Best Practice Guidelines for Immunization \(including contraindications and precautions\)](#)
- [Vaccine information statements](#)
- [Manual for the Surveillance of Vaccine-Preventable Diseases \(including case identification and outbreak response\)](#)

Last Reviewed: November 16, 2023

How helpful was this page?



Not helpful

Very helpful

Immunization Case Scenarios

Case I

You are seeing 3 yo Dana for a well child visit. She has never received any vaccine, but after much soul-searching, her parents have agreed to ensure she is up to date. What vaccine would you prescribe today?

When would you schedule the next visit? What would you prescribe at that visit?

Case II

You are seeing 4 yo DeAndre who has sickle cell anemia. He has received DTaP x 4, IPV x 3, MMR, Varivax, and Hib x 3. What vaccines would you prescribe today?

Case III

You are seeing 17 yo Anthony for a college physical. He has received DTaP x 5, IPV x 4, MMR x 2, Hib x 2. What vaccines would you prescribe?

Case IV

You are seeing 22 mo Maggie who was adopted from China. Her translated immunization booklet indicates

that she received DTap x 3, IPV x 3, Hib x 3, HepB x 3, MMR x 1, **BCG x 1**, and varivax x 1. What would you prescribe today?

Board Review Questions:

1. A family comes to your office for consultation regarding a 3-week trip to India they are planning to take in 3 months. The children, a 9-year-old boy and a 7-month-old girl, are well, and their immunizations are up to date.

Of the following, the MOST appropriate prophylaxis to provide in preparation for travel is :

- A. chloroquine for both children
- B. hepatitis A vaccination for both children
- C. measles vaccination for the girl
- D. polio vaccination for the boy
- E. typhoid vaccine for both children

2. A 14-year-old girl presents to your emergency department for evaluation of a 3-week history of progressive episodes of coughing spasms. She reports several episodes of post-tussive vomiting and difficulty sleeping at night. She denies night sweats or weight loss and says she was previously well. She does not take any medications.

Of the following, the MOST important additional information to obtain is a history of:

- A. gastroesophageal reflux disease
- B. international travel over the past year
- C. pet or animal exposures
- D. spelunking trips in the last 6 months
- E. vaccinations received since 11 years of age

3. A 6-month-old boy presents to the emergency department with a 2-day history of fever and a 1-day history of left cheek swelling. You discover that his parents do not believe in providing their children with immunizations. Despite this, the boy has never been ill. He has two older siblings, and nobody is sick at home. The mother denies any recent bug bites or trauma to the area on his cheek. Physical examination reveals a mildly toxic-appearing child who has a temperature of 103.0°F (39.4°C), heart rate of 145 beats/min, respiratory rate of 26 breaths/min, and blood pressure of 80/45 mm Hg. His anterior fontanelle is slightly bulging, his tympanic membranes are erythematous, his left cheek is indurated and appears erythematous to slightly violaceous, and he is irritable.

Of the following, the MOST likely organism to cause this child's illness is:

- A. Haemophilus influenzae type b
- B. Neisseria meningitidis
- C. Staphylococcus aureus
- D. Streptococcus pneumoniae
- E. Streptococcus pyogenes

4. A mother calls you to report that her 7-year-old son came home with a notice from school stating that a child in his class was diagnosed with mumps. The mother does not know the immunization status of the infected child but states that her son has received two measles-mumps-rubella (MMR) vaccines and is up to date on all his other immunizations. Her son has been asymptomatic, with no fever or other systemic complaints.

Of the following, the MOST appropriate action is to:

- A. administer a dose of mumps immune globulin to her son
- B. confirm that her son has received two doses of MMR vaccine
- C. keep her son home from school for 9 days to observe for the development of symptoms
- D. treat her son with a course of ribavirin
- E. vaccinate her son immediately with another dose of MMR to prevent infection from this exposure

5. You are hiring a pediatrician as a hospitalist at a community hospital.

Of the following, the disease for which immune status MUST be documented at the time of employment is:

- A. diphtheria
- B. hepatitis A
- C. measles
- D. meningococcal disease
- E. tetanus